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Hypolipidemic effectAbstract Objective: The present study was aimed to compare the effect of calcium channel
blocker (Amlodipine, Cilnidipine and Diltiazem) on lipid profiles of hypertensive rats fed with high
fat diet for four weeks.
Methods: Hypertensive rats were randomly allocated into four groups and except hypertensive rats
remaining all groups received high fat diet for 4 weeks. At the end of protocol blood pressure was
measured by tail cuff method and blood is withdrawn from the retro-orbital puncture, separated
serum is used for the assessment of various biochemical parameters. Finally liver and aorta isolated
for histological changes.
Results: Calcium channel blocker significantly reduces the lipid levels raised in hypertensive rats
fed with high fat diet and also restore the pathological changes of aorta and liver tissues.
Conclusion: These results indicate that they have a lipid lowering effect due to effect on different
stages of metabolism of lipids.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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nd/4.0/).1. Introduction
Calcium channel blockers (CCBs) are commonly used for var-
ious cardiovascular diseases like hypertension and ischaemic
heart disease.1 They are chemically classified into phenylalky-lamines, dihydropyridines, and benzothiazepines.2 Even
though hypertension participated in the progression of
atherosclerosis, the exact mechanism hasn’t been ruled out
yet.3 Hence the effect of calcium antagonists on serum lipids
and lipoproteins is of increasing interest. Current therapeutic
interventions for the prevention of cardiovascular disease are
directed at established risk factors such as hypertension, dys-
lipidemia (elevated low density lipoprotein [LDL]-cholesterol,
triglycerides as well as decreased high-density lipoprotein
[HDL]-cholesterol), and hyperglycaemia.4
138 N.B. Dangi et al.Over the past 30 years, considerable experimental and clin-
ical evidence has accumulated to support the suggestion that
calcium channel blockers (CCBs) have significant anti-
atherosclerotic effects that are independent of their hypoten-
sive effects.5
The accumulation of information in the last decade has sug-
gested several cellular mechanisms for CCBs which may influ-
ence atheroma;6 (a) Inhibition of vascular smooth muscle cell
proliferation and migration (b) inhibition of calcium influx
and deposition in the arterial wall (c) inhibition of synthesis
and deposition of extracellular matrix (d) enhanced removal
and degradation of cholesterol rich lipoproteins (e) protection
of LDL from oxidation (f) inhibition of platelet activation and
(g) preservation of endothelial function and hemodynamic
effect.
The present study investigates the comparative effect of
Amlodipine, Diltiazem and Cilnidipine on the lipid profile of
rat fed with high cholesterol diet.7 Amlodipine is a widely used
drug for hypertension and Cilnidipine is a new calcium channel
blocker approved for treatment of hypertension, whereas Dil-
tiazem is used for various other cardiovascular diseases. Stud-
ies also include a histopathological investigation to assess
cellular damage and improvement after the drug treatment in
different groups.
2. Materials and methods
2.1. Chemicals
Cholesterol, sodium cholate, cocoa butter and coconut oil
were purchased from national chemicals, Baroda. All other
reagents and chemicals obtained were of analytical grade.
Amlodipine was dissolved in 0.5% DMSO solution and
diluted to required volume with water. Diltiazem was freely
dissolved in distilled water; Cilnidipine was prepared in a
0.5% DMSO solution.
2.2. Animals
All experiments and protocols described in the present study
were approved by the Institutional Animal Ethics Committee
(IAEC) of Pharmacy Department, The M.S. University of
Baroda and with permission from the Committee for the Pur-
pose of Control and Supervision of Experiments on Animals
(CPCSEA), Ministry of Social Justice and Empowerment,
Government of India. Healthy Wistar rats of either sex weigh-
ing between 200 and 300 g were housed in polypropylene cages
and maintained under standardized conditions (12-h light/dark
cycle, 24 ± 2 C, 35 to 60% humidity) and provided free
access to palleted CHAKKAN diet (Nav Maharashtra Oil
Mills Pvt. Ltd., Pune) and purified drinking water ad libitum.
All animals were acclimatized for one week before the experi-
ment started.
2.3. Induction of hypertension: DOCA-salt-induced hypertension
Hypertension was induced experimentally in Male Wistar rats
(200–250 g) by unilateral nephrectomy.8 Rats were anaes-
thetized with ketamine (100 mg/kg body weight), and a lateral
incision was made in the area overlying the kidney. The renalblood vessel was ligated with fine sterile silk thread and the
kidney was removed. The incision was sutured and closed with
Michel clips. All operated rats received an injection of ampi-
cillin (10 mg/kg, i.p.) daily for 5 days. Neosporin powder
(polymyxin B sulfate BP, zinc bacitracin BP, neomycin sulfate
IP) was applied locally to prevent infection. One week later,
Deoxycorticosterone acetate (DOCA) (20 mg/kg, twice a week;
s.c., for 4 weeks) dispersed in olive oil was injected into uni-
nephrectomized rats. A solution of 1% saline + 0.2% KCl
ad libitum was given instead of drinking water. In sham-
operated control animals, a similar procedure was performed
except the treatment with DOCA.
2.4. Composition of high cholesterol diet and its preparation
Cholesterol (0.5%), Sodium cholate (0.1%), Cocoa butter
(10%), Coconut oil (10%) and Pellet powder (79.4%)
2.5. Preparation of diet
79.4 gm. of pellet powder was mixed with 100 mg of sodium
cholate separately. Simultaneously 500 mg of cholesterol and
10 gm. of cocoa butter were dissolved in 10 ml of warm coco-
nut oil. This oil solution of cholesterol was added slowly into
the powdered mixer to obtain a soft homogenous cake. This
cake was molded into pellets.
2.6. Experimental design
Rats were randomly divided into the following groups. Each
group consists of six animals.
Group 1: Sham control: They were fed with standard labo-
ratory diet and water ad libitum for four weeks.
Group 2: DOCA induced hypertensive rats: They were fed
with high cholesterol diet +0.5% DMSO9 for four weeks.
Group 3: DOCA induced hypertensive rats + Amlodipine:
They were administered Amlodipine (5 mg/kg, p.o) for four
weeks along with high cholesterol diet.
Group 4: DOCA induced hypertensive rats + Diltiazem:
They were administered Diltiazem (30 mg/kg, p.o) for four
weeks along with high cholesterol diet.
Group 5: DOCA+ Cilnidipine: They were administered
Cilnidipine (10 mg/kg, p.o) for four weeks along with high
cholesterol diet.
2.7. Preparation of serum sample
At the end of 4th week, animals were fasted overnight and
hemodynamic study was carried out, then serum and tissue
were subjected to different biochemical analysis & histoarchi-
tecture study.
The blood samples were withdrawn from the retro-orbital
plexus under light ether anesthesia and allowed to clot for
10 min at room temperature. It was centrifuged at 2500
RPM for 20 min. The serum obtained was kept at 4 C until
used.
After blood collection, all the animals were sacrificed by
ether anesthesia followed by spinal dislocation. Liver and
aorta were removed in a chilled condition and immediately
placed in 10% buffered formalin, embedded in paraffin, cut
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Figure 2 Effect of calcium channel blockers on heart beats of
hypertensive rats fed with high cholesterol diet. (Values are
expressed as mean ± SEM for six rats, NS = non-significant;
(*P< 0.05, **P< 0.01, ***P< 0.001).
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Figure 3 Effect of calcium channel blockers on systolic blood
pressure of hypertensive rats fed with high cholesterol diet. (Values
are expressed as mean ± SEM for six rats, NS = non-significant;
(*P< 0.05, **P< 0.01, ***P< 0.001).
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eosin. The slides were examined with a Magnus microscope.
The sections were observed under 40 and 100
magnifications.
2.8. Hemodynamic and biochemical parameters
2.8.1. Hemodynamic study
Arterial blood pressure was measured by non-invasive (indi-
rect or tail-cuff) method. Rats were trained for at least one
week until the blood pressure was steadily recorded with min-
imal stress and restraint. The first cardiovascular parameters
were discarded and the mean of five or six subsequent mea-
surements were recorded. Cardiovascular parameters (systolic,
diastolic, mean blood pressure, and heart rate) were measured
at the end of treatment by using Letica 5002 Storage Pressure
Meter (Panlab Blood Pressure Recorder model LE 2002 N,
Barcelona, Spain).
2.8.2. Serum parameters
Serum was used for measurement of Total cholesterol, High
Density Lipoprotein (HDL) cholesterol, triglycerides by using
kits supplied by Span Diagnostic Ltd. whereas low density
lipoprotein (LDL) cholesterol and very low density lipoprotein
(VLDL) cholesterol were calculated by Friedewald’s
formula.10
2.9. Statistical analysis
All the data were expressed as mean ± SEM. Statistical signif-
icance between more than two groups were tested using a one-
way ANOVA followed by the Bonferroni multiple comparison
test as appropriate using computer based fitting program
(Prism, Graph-pad). Differences were considered statistically
significant when P< 0.05.
3. Results
Administration of high cholesterol diet for four weeks showed
a significant increase (P< 0.001) in body weight in the sham
group compared to DOCA induced hypertensive rats. The cal-
cium channel blockers treatment showed a significant decrease
in body weight(P< 0.05, P< 0.01) after four weeks of treat-Effect of calcium channel blockers on body
weight changes
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Figure 1 Comparative study of change in body weight in
control, high cholesterol diet and treated groups (Values are
expressed as mean ± SEM for six rats, NS = non-significant;
(*P< 0.05, **P< 0.01, ***P< 0.001).
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Figure 4 Effect of calcium channel blockers on diastolic blood
pressure of hypertensive rats fed with high cholesterol diet. (Values
are expressed as mean ± SEM for six rats, NS = non-significant;
(*P< 0.05, **P< 0.01, ***P< 0.001).ment as compared to DOCA induced hypertensive rats
(Fig. 1).
Heart rate, systolic and diastolic blood pressure were signif-
icantly increased in hypertensive rats fed with high fat diet.
Amlodipine, Cilnidipine and Diltiazem treated groups showed
a significant decrease compared to HCD control (Figs. 2–4).
Total serum cholesterol was significantly (P< 0.001)
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Figure 5 Histopathology of cross section of aorta wall stained by hematoxylin–eosin staining of hypertensive rat fed with high
cholesterol diet.
140 N.B. Dangi et al.increased after four weeks of treatment with high cholesterol
diet in DOCA induced hypertensive rats compared to the sham
group. Amlodipine, Diltiazem and Cilnidipine treated groups
showed a significant (P< 0.05, P< 0.01) decrease in serum
total cholesterol after four weeks compared to DOCA induced
hypertensive rats.
Serum triglyceride levels were significantly (P< 0.001)
increased in DOCA induced hypertensive rats after four weeks
of treatment with high cholesterol diet compared to the sham
group. Treatment with Amlodipine, Diltiazem and Cilnidipine
showed a significant decrease (P< 0.05, P< 0.01, P< 0.001)
in TG level as compared to DOCA induced hypertensive rats.
Serum LDL-C levels were increased significantly (P< 0.001)
after four weeks of treatment with high cholesterol diet in
DOCA induced hypertensive rats compared to the sham
group. Amlodipine, Diltiazem and Cilnidipine treated groupshowed a significant decrease (P< 0.05, P< 0.001) in LDL-
C level after four weeks as compared to DOCA induced hyper-
tensive rats. VLDL-C showed a significant (P< 0.001)
increase in the HCD group compared to the control. However,
Amlodipine treatment does not show significant changes
whereas, Diltiazem and Cilnidipine treated groups showed a
significant (P< 0.01) decrease in VLDL-C level after four
weeks compared to the HCD control.
Serum HDL-C was decreased significantly (P< 0.001)
after four weeks of treatment with high cholesterol diet in
DOCA induced hypertensive rats compared to the sham
group. Significant increase in HDL-C (P< 0.01) was observed
with Amlodipine Cilnidipine treated groups whereas, Dilti-
azem treated groups showed no significant change after four
weeks of treatment compared to DOCA induced hypertensive
rats.
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Figure 6 Histopathology of cross section of liver stained by hematoxylin–eosin staining of hypertensive rat fed with high cholesterol diet.
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3.1.1. Aorta: (Fig. 5)
HCD showed the increase in lipid deposition and endothelial
dysfunction compared to the control after four weeks.
Amlodipine, Diltiazem and Cilnidipine treated groups showed
decreased lipid deposition and endothelial dysfunction com-
pared to HCD control.
3.1.2. Liver: (Fig. 6)
HCD showed the increase in intracellular space compared to
the control after four weeks. Amlodipine, Diltiazem and Cilni-
dipine treated groups showed decreased intracellular space
compared to HCD control.4. Discussion
Today, in most of the developed and developing countries
hyperlipidaemia and thereby atherosclerosis is the leading
cause of cardiac illness and deaths.11,12 In 1984 it was demon-
strated for the first time that there exists a link between serum
cholesterol levels and risk of coronary heart disease (CHD).13
Worldwide, it causes deaths almost twice as many as those
caused by cancer and 10 times as many as those caused by
accidents.
In recent years the role of calcium antagonists is expanding
into long term therapy of cardiovascular diseases like hyper-
tension and ischemic heart diseases. Hypertension is a driver
of the development of atherosclerosis underlying cardiovascu-
Table 1 Effect of calcium channel blockers on lipid profiles of hypertensive rats fed with high cholesterol diet. (Values are expressed
as mean ± SEM for six rats, NS = non-significant; (*P< 0.05, **P< 0.01, ***P< 0.001).
Control HCD Amlodipine Diltiazem Cilnidipine
TC mg/dl 40.11 ± 1.999 122.2 ± 5.608*** 93.01 ± 5.715** 99.76 ± 3.981* 90.12 ± 4.395**
TG mg/dl 42.54 ± 4.182 230.6 ± 23.20*** 164.1 ± 12.51* 145.1 ± 3.930** 134.1 ± 5.786***
LDL mg/dl 17.24 ± 1.301 65.73 ± 2.871*** 31.15 ± 12.00* 35.30 ± 6.090* 14.49 ± 1.878***
VLDL mg/dl 8.503 ± 0.8359 53.42 ± 8.012*** 39.39 ± 3.698NS 27.02 ± 2.244** 26.06 ± 1.277**
HDL mg/dl 53.05 ± 5.627 21.67 ± 0.8436*** 48.21 ± 3.889** 41.13 ± 5.628NS 48.83 ± 3.024**
142 N.B. Dangi et al.lar disease, although the molecular mechanisms and associa-
tions have not been resolved.14 Hence the effect of calcium
antagonists on serum lipids and lipoproteins is of increasing
interest. The present study reported the influence of various
calcium antagonists on the lipid profile of hypertensive rat
fed with high cholesterol diet, using a single experimental ani-
mal model. This is the best animal model for studying related
to intermediary metabolism.15
A specially prepared diet was used for induction of hyper-
cholesterolemia in rats with a duration of four weeks for main-
tenance of sustained hypercholesterolemia.
Body weight was significantly increased in the HCD group
whereas, Amlodipine, Cilnidipine and Diltiazem treated
groups showed a decrease when compared to the HCD group.
Serum total cholesterol levels were increased in the HCD
group.16 These changes are associated with a phenomenon that
excessive load of cholesterol in the liver above the acceptable
level of its normal process causes the system to be unable in
metabolize the lipids resulting in high cholesterol return in
the circulating blood.17 Serum total cholesterol was signifi-
cantly decreased by Amlodipine, Cilnidipine and Diltiazem
treatment compared with the HCD group. This effect may
be due to the activation of more than one pathway, like activa-
tion of lysosomal cholesterol ester hydrolase and prevention of
induction of HMG CoA gene so as to reduce cellular choles-
terol biosynthesis18 (see Table 1).
Decreased serum LDL-Cholesterol might be due to the
increased expression of LDL–receptors on the cell surface
leading to increase in uptake and metabolism of LDL-
Cholesterol following calcium channel blocker therapy.19,20
HDL-C mediates the process termed reverse cholesterol
transport. Cholesterol in peripheral cells is transported from
the plasma membranes of peripheral cells to the liver by an
HDL-C.21 Thus, HDL-C causes removal of cholesterol from
the body to the liver where it gets excreted and reduced the risk
of atherosclerosis.22 Significant change was observed in HDL-
C in the HCD group compared to the control. Amlodipine and
Cilnidipine only show a significant increase in HDL-C but in
the remaining treatment groups Diltiazem treatment showed
no significant change in serum HDL-C.
Dihydropyridines increase the triglyceride lipase to cause a
rapid breakdown of triglycerides and mobilization of free fatty
acids; thereby leading to a fall in levels of serum triglycerides.23
Alternatively calcium channel antagonists could remove
triglycerides by vasodilation and expanding the capillary bed
where the enzyme exerts its activity.24 Serum VLDL-C levels
were increased in the HCD group. Amlodipine treatment did
not show significant changes but Diltiazem and Cilnidipine
treated groups showed a decrease in serum VLDL-C.
Findings of the present study correlate with previous
studies and it was found that there is a similarity betweenthe studies.25,26 In previous studies high cholesterol diet altered
the lipid profile in normal rats whereas calcium channel block-
ers decreased the lipid profile of patients. In our study there is
a correlation between lipid profile, hemodynamic parameters
and calcium channel blockers of hypertensive rats and the
main aim is a comparative study of the three different classes
of calcium channel blocker with the evidence of histopatholog-
ical examination of the aorta and liver.
5. Conclusion
This study explains the comparative study of CCB (Amlodip-
ine, Diltiazem and Cilnidipine) on the lipid profile of rats fed
with high cholesterol diet. CCB treatment decreases serum
cholesterol, triglyceride, LDC-C, VLDL-C and increases the
HDL level. Cilnidipine showed more favorable effect on lipid
level of rats when compared to Amlodipine and Diltiazem.
Finally, the new generation of dihydropyridines has more
advantage in favor of lipid lowering effect besides antihyper-
tensive property. The more salient question of whether these
effects are clinically relevant to patients taking therapeutic
doses of CCBs is only now beginning to be addressed.
Although our study showed Dihydropyridines are more bene-
ficial in reducing lipid levels than other Benzothiazepines like
Diltiazem.
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